Sandoz Group AG Stock

Equities

SDZ

CH1243598427

Pharmaceuticals

Market Closed - Swiss Exchange 11:30:02 2024-05-17 am EDT 5-day change 1st Jan Change
31.99 CHF -0.87% Intraday chart for Sandoz Group AG -1.72% +18.22%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 * 10.29B 9.35B Sales 2025 * 10.96B 9.96B Capitalization 15.15B 13.76B
Net income 2024 * 743M 675M Net income 2025 * 997M 906M EV / Sales 2024 * 1.77 x
Net Debt 2024 * 3.1B 2.82B Net Debt 2025 * 2.71B 2.47B EV / Sales 2025 * 1.63 x
P/E ratio 2024 *
20.4 x
P/E ratio 2025 *
15.2 x
Employees 22,633
Yield 2024 *
1.8%
Yield 2025 *
2.36%
Free-Float 91.55%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.87%
1 week-1.72%
Current month+2.70%
1 month+11.46%
3 months+11.42%
6 months+25.25%
Current year+18.22%
More quotes
1 week
31.61
Extreme 31.61
32.80
1 month
29.07
Extreme 29.07
32.80
Current year
25.33
Extreme 25.33
32.80
1 year
22.70
Extreme 22.7
32.80
3 years
22.70
Extreme 22.7
32.80
5 years
22.70
Extreme 22.7
32.80
10 years
22.70
Extreme 22.7
32.80
More quotes
Date Price Change Volume
24-05-17 31.99 -0.87% 1,173,945
24-05-16 32.27 +0.03% 1,101,005
24-05-15 32.26 +1.03% 802,908
24-05-14 31.93 -1.02% 696,727
24-05-13 32.26 -0.89% 702,718

Delayed Quote Swiss Exchange, May 17, 2024 at 11:30 am EDT

More quotes
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
35.25 USD
Average target price
39.18 USD
Spread / Average Target
+11.17%
Consensus

Quarterly revenue - Rate of surprise

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW